Shire to purchase Jerini for €349M

07/6/2008 | (India) · Bloomberg

U.K. drug company Shire will pay €349 million in cash to acquire Jerini, maker of Firazyr, a treatment for hereditary angioedema. Shire is working with the German drugmaker to boost the efficacy of the medicine after it failed in a late-stage study to outperform placebo. Firazyr is expected to generate as much as $400 million a year once it reaches the European market.

View Full Article in: (India) · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care